Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer

Table 1

Clinical information for the TMAs: (A) TMA #1, (B) TMA #2, (C) TMA #3, and (D) TMA #4.

(A) TMA #1 clinical information
Median age (range)		50 (28–74)
Grade	1; 2; 3	0; 6; 51
Chemotherapy		FEC
(B) TMA #2 clinical information
Median age (range)		49 (28–74)
Grade	1; 2; 3	0; 7; 57
Chemotherapy		FEC
(C) TMA #3 clinical information
Median age (range)		45 (28–76)
Grade	1; 2; 3; Not stated	0; 6; 105; 1
Chemotherapy	CMF; FEC-docetaxel; Tamoxifen/radiotherapy	77; 18; 17
(D) TMA #3 clinical information
Median age (range)		54 (36–82)
Grade	1; 2; 3	0; 6; 56
Chemotherapy	FEC; AC; TACT-FEC; None	27; 14; 8; 13